导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -11.97% | 3880/4773 |
| 近一周 | -2.40% | 3822/5465 |
| 近一月 | -8.62% | 5010/5421 |
| 近一季 | -17.48% | 4609/5231 |
| 近半年 | -14.76% | 4014/4920 |
| 近一年 | -12.93% | 3586/4394 |
| 近两年 | 40.28% | 1888/2954 |
| 近三年 | 11.51% | 1719/2253 |
| 成立以来 | 63.23% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.33% 3135/4961 |
13.84% 1931/5312 |
- - |
- - |
| 2025 | 19.43% 2219/4813 |
-0.70% 2365/3635 |
-1.11% 3114/4076 |
28.84% 1246/4524 |
-5.60% 3575/4813 |
| 2024 | 10.09% 1436/3463 |
-4.84% 1777/2808 |
-4.97% 1603/3014 |
23.47% 395/3129 |
-1.40% 1686/3463 |
| 2023 | -10.27% 1282/2656 |
6.76% 649/2280 |
-5.90% 1555/2385 |
-7.98% 1652/2515 |
-2.93% 557/2655 |
| 2022 | -24.80% 1258/2207 |
-20.81% 1579/1919 |
4.10% 1059/2016 |
-13.32% 883/2113 |
5.25% 478/2208 |
| 2021 | -0.33% 749/1822 |
-6.22% 987/1255 |
18.70% 171/1330 |
-12.76% 1312/1466 |
2.63% 550/1822 |
| 2020 | 54.55% 143/1250 |
3.55% 115/1028 |
27.98% 119/1067 |
6.35% 851/1164 |
9.65% 626/1184 |
| 2019 | - - |
- - |
- - |
6.23% 132/850 |
9.11% 260/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 华夏创业板价值ETF联接C VS. 长安沪深300非周期A(740101) |